Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil

Journal of Urology

Volumn 156, Issue 1, 1996, Pages 18-21

  Hofmockel, G ^a   Langer, W ^a   Theiss, M ^a   Gruss, A ^a   Frohmuller H G W ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

carcinoma, renal cell; fluorouracil; interferon alpha; interleukin 2; kidney neoplasms

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL KILLING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029993158     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65926-3     Document Type: Article

References (33)

1. Hofmockel, G., Wirth, M. P., Heimbach, D. and Frohmüller, H. G.: Low-dose cyclic interferon gamma treatment in metastatic renal cell carcinoma. Urologe A, 32: 290, 1993.
2. deKernion, J. B.: Treatment of advanced renal cell carcinoma - traditional methods and innovative approaches. J. Urol., 130: 2, 1983.
3. Bono, A. V.: Steroid hormones and hormonal treatment in renal cell carcinoma. In: Tumors of the Kidney. Edited by J. B. deKernion and M. Pavone-Macaluso. Baltimore: Williams & Wilkins, chapt. 14, pp. 205-227, 1986.
4. deRiese, W., Allhoff, E., Kirchner, H., Stief, C. G., Atzpodien, J., Maschek, H. and Jonas, U.: Complete spontaneous regression in metastatic renal cell carcinoma - an update and review. World J. Urol., 9: 184, 1991.
5. Wirth, M. P.: Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. N. Amer., 20: 283, 1993.
6. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S. and White, D. E.: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7: 1863, 1989.
7. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H. and White, D. E.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J.A.M.A., 271: 907, 1994.
8. West, W. H., Tauer, K. W., Yannelli, J. R., Marshall, G. D., Orr, D., Lewis, M., Birch, R. and Oldham, R. K.: Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma. Molec. Biother., 1: 268, 1989.
9. Atzpodien, J., Körfer, A., Franks, C. R., Poliwoda, H. and Kirchner, H.: Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet, 335: 1509, 1990.
10. Hofmockel, G., Theiss, M., Bussen, D., Wirth, M. P. and Frohmüller, H. G.: Treatment of advanced renal cell carcinoma with subcutaneous administration of interleukin-2 and interferon-alpha. Urologe A, 33: 434, 1994.
11. Vuoristo, M., Jantunen, I., Pyrhönen, S., Muhonen, T. and Kellokumpu-Lehtinen, P.: A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma. Eur. J. Cancer, 30A: 530, 1994.
12. Atzpodien, J., Lopez Hanninen, E., Kirchner, H., Bodenstein, H., Pfreundschuh, M., Rebmann, U., Metzner, B., Illiger, H. J., Jakse, G., Niesel, T., Scholz, H.-J., Wilhelm, S., Pielmeier, T., Zakrzewski, G., Blum, G., Beier, J., Müller, G.-W., Duensing, S., Anton, P., Allhoff, E., Jonas, U. and Poliwoda, H.: Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol., 13: 497, 1995.
13. Atzpodien, J., Kirchner, H., Hänninen, E. L., Deckert, M., Fenner, M. and Poliwoda, H.: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur. J. Cancer, suppl. 5, 29A: S6, 1993.
14. Brunda, M. J., Bellantoni, D. and Sulich, V.: In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer, 40: 365, 1987.
15. Atzpodien, J., Shimazaki, C., Wisniewski, D., Gulati, S., Bührer, C., Öz, S., Link, H., Poliwoda, H., Welte, K. and Clarkson, B.: Interleukin-2 and Interferon-a in der adoptiven Immuntherapie des Plasmozytoms: Ein experimentelles Modell. In: Leukämien und Lymphome. Edited by D. Lutz, R. Heinz, H. Novotny and A. Stacher. Baltimore: Urban & Schwarzenberg, pp. 211-212, 1988.
16. Atkins, M. B., Sparano, J., Fisher, R. I., Weiss, G. R., Margolin, K. A., Fink, K. I., Rubinstein, L., Louie, A., Mier, J. W. and Gucalp, R.: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J. Clin. Oncol., 11: 661, 1993.
17. Lissoni, P., Barni, S., Ardizzoia, A., Andres, M., Scardino, E., Cardellini, P., Della Bitta, R. and Tancini, G.: A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma. Tumori, 79: 397, 1993.
18. Huland, E., Heinzer, H. and Huland, H.: Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J. Cancer Res. Clin. Oncol., 120: 221, 1994.
19. Wadler, S. and Schwartz, E. L.: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res., 50: 3473, 1990.
20. Reiter, Z., Ozes, O. N., Blatt, L. M. and Taylor, M. W.: A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity. Clin. Immunol. Immunopath., 62: 103, 1992.
21. Palmer, P. A., Atzpodien, J., Philip, T., Negrier, S., Kirchner, H., Von der Maase, H., Geertsen, P., Evers, P., Loriaux, E., Oskam, R., Roest, G., Vinke, J. and Franks, C. R.: A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother., 8: 123, 1993.
22. White, R. L., Jr., Schwartzentruber, D. J., Guleria, A., MacFarlane, M. P., White, D. E., Tucker, E. and Rosenberg, S. A.: Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer, 74: 3212, 1994.
23. Rackley, R., Novick, A., Klein, E., Bukowski, R., McLain, D. and Goldfarb, D.: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J. Urol., 152: 1399, 1994.
24. Belldegrun, A., Koo, A. S., Bochner, B., Figlin, R. and deKernion, J. B.: Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy. Eur. Urol., suppl. 2, 18: 42, 1990.
25. Palmer, P. A., Vinke, J., Philip, T., Negrier, S., Atzpodien, J., Kirchner, H., Oskam, R. and Franks, C. R.: Prognostic factors of survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol., 3: 475, 1992.
26. Lissoni, P., Scardino, E., Favini, P., Barni, S., Tancini, G., Baccalin, A., Verweij, F., Strada, G., Musci, R. and Rocco, F.: Prognostic predictive factors of the clinical response to immunotherapy with subcutaneous interleukin-2, in patients with metastatic renal cell carcinoma: analysis of 60 cases. Arch. Ital. Urol., 67: 149, 1995.
27. Mani, S., Todd, M. B., Katz, K. and Poo, W.-J.: Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J. Urol., 154: 35, 1995.
28. Lissoni, P., Barni, S., Ardizzoia, A., Crispino, S., Paolorossi, F., Andres, M., Scardino, E. and Tancini, G.: Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology, 51: 59, 1994.
29. Belldegrun, A., Figlin, R., Haas, G. and deKernion, J.: Immunotherapy for metastatic renal-cell carcinoma. World J. Urol., 9: 157, 1991.
30. Pittman, K. and Selby, P.: The management of renal cell carcinoma. Critical Rev. Oncol. Hematol., 16: 181, 1994.
31. Sherry, R. M., Pass, H. I., Rosenberg, S. A. and Yang, J. C.: Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer, 69: 1850, 1992.
32. Kim, B. and Louie, A. C.: Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch. Surg., 127: 1343, 1992.
33. Jones, M., Philip, T., Palmer, P., von der Maase, H., Vinke, J., Elson, P., Franks, C. R. and Selby, P.: The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother., 8: 275, 1993.